Previous 10 |
home / stock / nrxpw / nrxpw news
Results from ACTIV-3b study using ZYESAMI for treatment of hospitalized patients with Covid-19 are expected in 1st half of 2022. NDA approval expected in 2nd half of 2022 with successful data. Initiation of phase 3 study using NRX-101 for treatment of hospitalized bipolar depression p...
NRx Pharmaceuticals, Inc. (NRXP) Q3 2021 Earnings Conference Call November 16, 2021 08:30 ET Company Participants Eric Goldstein - Managing Director, LifeSci Advisors Jonathan Javitt - Chairman and Chief Executive Officer Randy Guggenheimer - Chief Business Officer Presentation Operator Good ...
NRx Pharmaceuticals, Inc. (NRXP) Q2 2021 Results Conference Call August 17, 2021 08:30 AM ET Company Participants Eric Goldstein - Managing Director, LifeSci Advisors Jonathan Javitt - Chairman and Chief Executive Officer Randy Guggenheimer - Chief Business Officer Robert Besthof - Chief Comm...
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc. Warrant Company Name:
NRXPW Stock Symbol:
NASDAQ Market:
NRX Pharmaceuticals Inc. Warrant Website: